If the phenotype of WT enzymatic activity that is observed in vitro is also present in the corresponding XLSA patients, then these mutations must be decreasing heme production through means other than impacting ALAS2 activity. Here, ALAS2 is linked to X-linked sideroblastic anemia 1.